Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin for Long COVID Syndrome

NCT06907251 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT06907251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin for Long COVID Syndrome
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 30, 2029
Enrollment
192 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid - 19, long covid syndrome, sars cov-2